New Delhi: Bharat Biotech, the corporate which manufactures COVID-19 vaccine Covaxin, has determined to ramp up its production to manufacture additional 200 million doses per year.
The COVID-19 vaccines might be produced at Chiron Behring Vaccines, Ankleshwar, Gujarat, a wholly-owned subsidiary of Bharat Biotech.
To this impact Bharat Biotech issued an announcement saying: “The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on inactivated Vero Cell Platform Technology under stringent levels of GMP and biosafety. Product availability at Ankleshwar to commence from the fourth quarter of 2021.”
The additional quantity of Covaxin doses takes the manufactured quantity up to 1 billion doses per annum. Product availability at Ankleshwar to begin from This fall 2021, it added.
“Adding Chiron Behring to this up of high containment BSL rated GMP facilities that are required to manufacture Covaxin and effectively takes the volume upto-one billion doses per annum with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety,” the assertion learn.
The firm stated that it has already deployed a number of production traces at its Hyderabad and Bengaluru campuses as properly.
